609 related articles for article (PubMed ID: 30940117)
1. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
2. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
3. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
[TBL] [Abstract][Full Text] [Related]
4. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
5. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Ueno D; Yao M; Tateishi U; Minamimoto R; Makiyama K; Hayashi N; Sano F; Murakami T; Kishida T; Miura T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2012 May; 12():162. PubMed ID: 22551397
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance and prognostic value of preoperative
Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
[TBL] [Abstract][Full Text] [Related]
7. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of SUVmax values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma.
Gulturk I; Yilmaz M; Tacar SY; Tural D
Q J Nucl Med Mol Imaging; 2023 Sep; 67(3):223-229. PubMed ID: 34881845
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K
Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323
[TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma.
Pankowska V; Malkowski B; Wedrowski M; Wedrowska E; Roszkowski K
Clin Exp Med; 2019 Feb; 19(1):143-148. PubMed ID: 30488140
[TBL] [Abstract][Full Text] [Related]
13. Lesion detection by [
Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
Zhu H; Zhao S; Zuo C; Ren F
AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
[No Abstract] [Full Text] [Related]
17. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.
Kakizoe M; Yao M; Tateishi U; Minamimoto R; Ueno D; Namura K; Makiyama K; Hayashi N; Sano F; Kishida T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Taguri M; Morita S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2014 Jun; 14():390. PubMed ID: 24885730
[TBL] [Abstract][Full Text] [Related]
18. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
19. Metabolic activity by
Kaira K; Higuchi T; Naruse I; Arisaka Y; Tokue A; Altan B; Suda S; Mogi A; Shimizu K; Sunaga N; Hisada T; Kitano S; Obinata H; Yokobori T; Mori K; Nishiyama M; Tsushima Y; Asao T
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):56-66. PubMed ID: 28828507
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
